Aspirus Research
Institute is seeking participants for a clinical study that has the potential
to improve future treatment options for people living with cardiovascular
disease. If you have had a heart attack or stroke, or have poor circulation,
you may be eligible for the study.
The REDEFINE 3 Study
will look at the safety and potential benefits of cagrilintide and semaglutide
(CagriSema) on cardiovascular events, like heart attack and stroke, in people
living with cardiovascular disease. During the study, researchers will track
cardiovascular events (heart attack, stroke, or heart-related deaths) as well
as changes in body weight and A1C.
Participants may
qualify if they:
- Had a stroke, heart
attack, or have poor circulation (peripheral artery disease)
- Are 55 years of age
or older
- Are considered
overweight or living with obesity (BMI>25)
- Have type 2 diabetes
- Can have chronic
kidney disease
- Can attend regular
clinic visits and receive phone calls over 4 - 4.5 years, depending on study
start date
The study sponsor,
Novo Nordisk, expects the study to last up to 4.5 years and enroll 7,000
participants in the United States and across the world.
“We are honored to
be selected and participate in this important clinical trial that applies the
latest research discoveries to help advance medicine,” said Aspirus study
principal investigator, Interventional Cardiologist, German Larrain, MD. “Study
participants can know they are helping others by contributing to this important
research.”
All patients
enrolled in the REDEFINE 3 study will be followed closely for up to four and a
half years. There are no costs associated with participation and patients are
reimbursed for all study-related visits.
For more information
about the REDEFINE 3 study, please contact visit aspirus.org/redefine3 or call
Aspirus Research Institute at 715.847.2273.